Enasidenib

Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2.